|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Revenues | |||||
| Product | |||||
| Royalty, contract and other revenues | |||||
| Total revenues | |||||
| Costs and expenses: | |||||
| Cost of goods sold | |||||
| Research and development expenses | |||||
| Acquired in-process research and development expenses | |||||
| In-process research and development impairments | |||||
| Selling, general and administrative expenses | |||||
| Total costs and expenses | |||||
| Operating income | |||||
| Interest expense | |||||
| Other (income) expense, net | |||||
| Income before income taxes | |||||
| Income tax (benefit) expense | |||||
| Net income | |||||
| Net loss attributable to noncontrolling interest | |||||
| Net income attributable to Gilead | |||||
| Basic earnings per share attributable to Gilead (in dollars per share) | |||||
| Diluted earnings per share attributable to Gilead (in dollars per share) | |||||
| Shares used in basic earnings per share attributable to Gilead calculation (in shares) | |||||
| Shares used in diluted earnings per share attributable to Gilead calculation (in shares) |
Loading...